FDA Vaccine Panel Says Dynavax’s Hepislav-B Meets Safety Requirements

Drug Industry Daily
A A
An FDA vaccine advisory panel voted 12-to-1 last Friday to recommend approval of Dynavax’s Hepislav-B in adults for the prevention of hepatitis B.

To View This Article:

Login

Subscribe To Drug Industry Daily